A year after shaking global markets, the US is back with a sharper trade move — this time targeting medicines. By imposing 100 percent tariffs on patented drugs, Washington is pushing companies to manufacture locally and reduce foreign dependence. India, however, finds itself in a relatively safe position for now. Its dominance in generic medicines, which are exempt from the tariffs, shields the bulk of its exports. But the relief may not last. The exemption is temporary, and a future review could change the game completely. Indian firms involved in branded drugs or pharmaceutical ingredients already face potential risks. The policy also shows a selective approach, with some countries receiving tariff relief. For India, this means negotiations and strategy will be key. The larger message is clear — global trade rules are shifting. India has breathing space, but it must prepare for a scenario where even its strongest sector faces pressure.